The human immunodeficiency virus type 1 (HIV-1) is the causative agent of one of the most dangeroushuman diseases - the acquired immune deficiency syndrome (AIDS). Over the past 30 years since thediscovery of HIV-1, a number of antiviral drugs have been developed to suppress various stages of the HIV-1 lifecycle. This approach has enabled the suppression of virus replication in the body, which significantly prolongs the life of HIV patients. The main downside of the method is the development of viral resistance to many anti-HIV drugs, which requires the creation of new drugs against drug-resistant viral forms effectively. This review summarizes current information on antiviral drugs in the US and focuses on the development and the nonclinical study concerns for antiviral drugs.